Related Experiment Videos
Novel molecular targets in the treatment of cardiac hypertrophy
Mark Luedde1, Hugo A Katus, Norbert Frey
1Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Insights
Left ventricular hypertrophy (LVH) initially compensates for heart stress but becomes maladaptive, leading to heart failure. Understanding its molecular pathways is key to developing new cardiovascular drugs.
Area of Science:
- Cardiology
- Molecular Biology
- Pathophysiology
Background:
- Left ventricular hypertrophy (LVH) is the heart's response to increased biomechanical stress, such as hypertension or valvular disease.
- Traditionally viewed as compensatory, sustained LVH is now recognized as a maladaptive process.
- LVH can lead to heart failure and sudden death, irrespective of the initial cause.
Purpose of the Study:
- To review recent insights into the molecular signaling pathways that mediate cardiac hypertrophy.
- To explore current and emerging therapeutic strategies for inhibiting cardiac hypertrophy.
- To identify potential targets for new cardiovascular drugs to prevent heart failure.
Main Methods:
- Review of recent clinical studies and animal models.
- Analysis of molecular signaling pathways involved in cardiac growth.
- Evaluation of therapeutic approaches to inhibit hypertrophy.
Main Results:
- Sustained cardiac hypertrophy is a maladaptive process contributing to heart failure.
- Significant research efforts have focused on deciphering the molecular basis of cardiac growth.
- Novel molecules regulating cardiac hypertrophy are being identified.
Conclusions:
- Targeting hypertrophic signaling pathways offers a promising strategy for preventing heart failure.
- Further research into molecular mechanisms can lead to novel cardiovascular therapeutics.
- Inhibiting maladaptive cardiac hypertrophy is crucial for improving patient outcomes.
Abstract:
Left ventricular hypertrophy represents the heart's response to increased biomechanical stress such as arterial hypertension or valvular heart disease. Cardiac hypertrophy has traditionally been considered a compensatory mechanism required to normalize wall tension and to maintain cardiac output. However, recent clinical studies as well as several animal models have shown that sustained cardiac hypertrophy is rather a maladaptive process, ultimately leading to heart failure and sudden death independent of the underlying cause of hypertrophy. Throughout the past decade, much effort has thus been spent on deciphering the molecular signaling pathways mediating cardiac growth. Identification of novel molecules regulating cardiac hypertrophy could offer the basis for a new generation of cardiovascular drugs. In this review we focus on recent insights into hypertrophic signaling and consider current and emerging approaches to inhibit hypertrophy with the ultimate goal to prevent or delay the onset of heart failure and sudden death in patients.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:26Heart Failure Drugs: Inotropic Agents
01:29Heart Failure II: Pathophysiology